Clinical trial
Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes
NCT00361296 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Terminated
Key facts
| NCT number | NCT00361296 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes |
| Official title | K562/GM-CSF Vaccination in Patients With Myelodysplastic Syndrome |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH Alliance for Cancer Gene Therapy |
| Status | Terminated |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Biological |
| Interventions | K562/GM-CSF cell vaccine |
| Enrollment | 9 |
| Start date | Sep 1, 2007 |
| Primary completion | Oct 1, 2009 |
| Completion | Jan 1, 2010 |
| First posted | Aug 8, 2006 |
| Last update posted | Mar 23, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: